patients, and through the use of new agents developed specifically to target autophagy, will the role of autophagy in human NASH be determined.

MARK J. CZAJA, M.D.
Department of Medicine and Marion Bessin Liver Research Center
Albert Einstein College of Medicine
Bronx, NY

References

1. Park HW, Park H, Semple IA, Jang I, Ro SH, Kim M, et al. Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers. Nat Commun 2014;5:4834.

2. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 2009;458:1131-1135.

3. Amir M, Czaja MJ. Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011;5:159-166.

4. Liu K, Zhao E, Ilyas G, Lalazar G, Lin Y, Haseeb M, et al. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Autophagy 2015;11:271-284.

5. Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ 2013;20:3-11.

6. Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. FASEB J 2010;24:3052-3065.

7. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011;53:131-140.

8. Zhang J, Li Y, Jiang S, Yu H, An W. Enhanced endoplasmic reticulum SERCA activity by overexpression of hepatic stimulator substance gene prevents hepatic cells from ER stress-induced apoptosis. Am J Physiol Cell Physiol 2014;306:C279-C290.

9. Fogari R, Maffioli P, Mugellini A, Zoppini A, Lazzari P, Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2012;24:164-171.

Author names in bold designate shared co-first authorship.

Copyright © 2015 by the American Association for the Study of Liver Diseases.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.27858
Potential conflict of interest: Dr. Czaja advises for and received grants from Verlyx.

Cell-Type Specific Functions of Epidermal Growth Factor Receptor Are Involved in Development of Hepatocellular Carcinoma

The inflammatory microenvironment is regulated by epidermal growth factor/epidermal growth factor receptor (EGF-EGFR) signaling and is associated with development of hepatocellular carcinoma (HCC). Precise mechanisms by which EGFR-dependent inflammation causes development of HCC have not been elucidated. In the recent Nature Cell Biology article, Lanaya et al. have shown that EGFR has different functions in Kupffer cells (KCs) and in hepatocytes and that the deletion of EGFR in microphages inhibited HCC, whereas deletion of EGFR in hepatocytes promotes HCC. The main results of this article are summarized in Fig. 1.

Development of HCC is a multistep process that involves alterations in a number of signaling pathways that synergistically contribute to liver cancer. HCC is usually associated with inflammation and cirrhosis as preneoplastic stages. Although the link between inflammation and HCC has been well established, molecular mechanisms are not completely understood. The EGFR is a transmembrane protein receptor that might be activated by EGF and by several additional extracellular ligands. This activation triggers a variety of signaling pathways, including signal transducer and activator of transcription 3, phosphoinositide 3-kinase, Src homology and collagen, Src homology 1, and SH2 domain-containing inositol 5-phosphatase 2 and casitas B-cell lymphoma E3 ubiquitin ligase. The growth promotion activities of EGFR have been initially investigated in a partial hepatectomy model of liver proliferation/regeneration. It has been shown that hepatocyte-specific deletion of EGFR1 in mice and rats significantly inhibits liver proliferation after surgical resections. In agreement with this growth promotion role of EGFR, further studies revealed that expression of EGFR and copy number of EGFR in HCC is associated with increased proliferation.
numbers are increased in patients with HCC, suggesting that EGFR plays a critical role in development of HCC. These observations prompted clinical trials with inhibitors of EGFR signaling, which, unfortunately, did not show improvements at advanced stages of HCC. It is interesting that further studies of effects of an inhibitor of EGFR, erlotinib, on liver cancer in an orthotopic rat model of HCC showed no antitumor effect.

These unsuccessful trials and negative results in animal models called into question whether our knowledge of the molecular basis for EGFR inflammation in HCC is sufficient for the generation of a strategy for treatments of patients with HCC. To better understand the role of EGFR in liver cancer, Lanaya et al. generated several animal models with a cell-type-specific deletion of EGFR within the liver and examined the development of liver cancer under conditions of diethylnitrosoamine (DEN)-mediated carcinogenesis. The response of wild-type (WT) livers to DEN includes DNA damage, apoptosis to replace the dead hepatocytes. The investigators showed that deletion of EGFR in all liver cells (EGFRWT mice) led to a significant decrease in proliferation and an increase in apoptosis. These initial studies were consistent with previous reports showing the tumor-promoting activities of EGFR. However, subsequent studies of liver tumor development in mice with deletion of EGFR in parenchymal cells (hepatocytes and bile duct cells, EGFRAlb hep mice) provided surprising observations that livers of EGFRAlb hep mice develop cancer significantly faster and with bigger sizes. The investigators also found that proliferation is significantly increased in livers of EGFRAlb hep mice during development of HCC. On the other hand, EGFRAlb hep mice were characterized by increased apoptosis, similar to EGFRAlbMs mice.

The striking differences in development of liver cancer between EGFRAlb hep mice and EGFRAlbMs mice prompted the investigators to perform a detailed examination into development of HCC at different additional time points after injection of DEN. It has been found that damaged areas and serum alanine aminotransferase/aspartate aminotransferase levels are significantly increased in these two animal models post-DEN injection and that that necrotic response is also much stronger in EGFRAlb hep and EGFRAlbMs mice, clearly indicating that expression of EGFR in hepatocytes is required for hepatoprotection. Searching for molecular differences between WT and EGFRAlb hep/EGFRAlbMs mice, the investigators examined levels of several cytokines and found that expression of interleukin (IL)-1β is significantly increased post-DEN injections in both EGFR mutant mouse models.

The differences in development of HCC between EGFRAlb hep and EGFRAlbMs mice suggested that EGFR also displays a functional role in non-parenchymal cells (NPCs). Immunohistochemical examination of NPCs in EGFRAlb hep tumors revealed a 4-fold increase of KCs/liver macrophages. To directly test the role of EGFR in KCs, the investigators have generated two additional mouse models that had a deletion of EGFR in both parenchymal cells and KCs and in KCs only. Examination of DEN-mediated liver tumor in these mice demonstrated that deletion of EGFR in KCs inhibits development of HCC. In agreement with these observations, expression of EGFR is increased in KCs of livers of WT mice post-DEN-mediated injury. A quite significant part of the article is a demonstration that EGFR-expressing KCs/liver macrophages are abundant in human HCC with poor prognosis. Examination of two large cohorts of patients with HCC from China and Europe showed that there is no relationship between increased expression of EGFR in hepatocytes to prognosis. However, tumor sections of HCC patients revealed high levels of EGFR in CD68 (macrophage marker)-positive cells, whereas adjacent nontumor tissues had no EGFR in CD68-positive cells. These studies demonstrated that increase of EGFR-positive macrophages in human HCC predicts a poor prognosis.

Identification of EGFR-expressing macrophages as the origin of HCC led to questioning the mechanisms by which EGFR signaling in macrophages promotes liver cancer. KCs produce IL-6 in response to IL-1β, which is derived from damaged hepatocytes. Examination of plasma of DEN-injected mice revealed a significant increase of IL-6 in EGFRAlb hep/EGFRAlbMs mice, but not in mice with macrophages-specific deletion of EGFR. Consistent with this observation, levels of IL-6 have been found to be increased in plasma of patients with HCC. Further studies showed that IL-1β induces IL-6 production in WT macrophages, but not in EGFR-deleted macrophages. In summary, the investigators showed that the mechanism of IL-1β-mediated activation of EGFR in macrophages includes induction of EGFR ligands and ADAM metallopeptidase domain 17 with subsequent phosphorylation of EGFR by p38 kinase.

The liver contains several cell types that communicate with one another and have the potential to be reprogrammed by specific transcription factors. Although cell-to-cell communications have been previously implicated in regulation of liver biology and development of liver cancer, the precise role of these communications in liver cancer has not been determined. The article by Lanaya et al. presents an excellent example of the studies of the role of EGFR in different cell types of the liver and the
significance of these observations for treatments of HCC. Given the tumor-promoting role of EGFR in macrophages, the therapeutic approaches should be designed for a specific inhibition of EGFR only in macrophages and should not affect EGFR in parenchymal cells given that the latter scenario might promote tumor-igenesis (see Fig. 1). The data from this article also suggest that inhibition of EGFR could be beneficial at early stages of liver cancer and that patients with advanced HCC will not benefit from EGFR-based therapy.

Nikolai A. Timchenko, Ph.D.
Division of Pediatric General & Thoracic Surgery
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

References

1. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 2014;10:972-981.
2. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 2014;346:17-23.
3. Berasian C, Avila MA. The EGFR signaling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastrointestol 2014;49:9-23.
4. Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A 2007;104:17081-17086.
5. Paranjpe S, Bowen WC, Tseng GC, Luo JH, Orr A, Michalopoulos GK. RNA interference against hepatic epidermal growth factor receptor has suppressive effect on liver regeneration in rats. Am J Pathol 2010;25:2669-2681.
6. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008;129:245-251.
7. Whittaker S, Marias R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
8. Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, Prager G, et al. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol 2012;57:592-599.

Author names in bold designate shared co-first authorship.

Copyright © 2015 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.

View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.27863
Potential conflict of interest: Nothing to report.